What are the side effects of Ofatumumab?

Common side effects of Ofatumumab are upper respiratory tract infection (nose and throat infection), urinary tract infection, injection site reactions (redness, pain, itching, and swelling), and injection-related Reactions (fever, headache, myalgia, chills and fatigue), neutropenia, etc. Adverse reactions that occurred after marketing include cardiac arrest (infusion-related cardiac events), mucocutaneous reactions (Stevens-Johnson syndrome, porphyria cutanea tarda).

Ofatumumab is an antiCD20 antibody that targets B cells. It is an IgG1 K human monoclonal antibody produced from a recombinant mouse cell line (NS0) through transgenic mice and hybridoma technology. Ofatumumab is indicated for the treatment of relapsed, progressive, or relapsed chronic lymphocytic leukemia (CLL) or CLL in treatment-naïve patients for whom fludarabine-based therapy is considered inappropriate. Ofatumumab may be used as monotherapy or in combination with other drugs, depending on the patient's condition and prior treatment history. It is also approved for the treatment of adult patients with relapsing multiple sclerosis (RMS).

The original drug of ofatumumab has been launched in China and has also been included in medical insurance. Only patients who meet the indications can be reimbursed. The price is around tens of thousands of yuan, and domestic purchase channels are relatively difficult. The European version of ofatumumab original drug specifications20mg/0.4mL each sold overseas may cost around RMB 16,000 (the price may fluctuate due to the exchange rate). It is expensive and there are currently no generics of ofatumumab. For more drug information and specific prices, please consult a medical consultant.